ORLANDO — Cytogenic and molecular factors can help predict prognosis of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allogeneic hematopoietic stem cell transplantation, according to retrospective study results presented at TCT | Transplantation & Cellular Therapy Meetings.

“Prognosis for patients with AML or myelodysplastic syndrome who relapse after transplant is very poor,” Corrado Zuanelli Brambilla, MD, of the adult bone marrow transplant service at Memorial Sloan Kettering Cancer Center, told Healio. “Time to relapse and type of relapse — minimal residual disease or morphologic relapse — were already known prognostic factors for post-relapse survival. We wanted to look at predictive or prognostic cytogenetic and molecular factors that correlated with those outcomes.”